BioSpace News Archive

Lone Star Bio

Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of five upcoming scientific presentations on its investigational drug LX9211, which is being evaluated in clinical trials for the treatment of diabetic peripheral neuropathic pain (DPNP).

September 7, 2023

·

5 min read

Business

PacBio Announces Collaboration with Leading Library Preparation Automation Partners

PacBio today announced that automation providers Hamilton, Integra, Revvity and Tecan have created fully automated protocols to prepare samples for sequencing on Revio and Sequel II and IIe systems.

September 7, 2023

·

5 min read

Genetown

Expansive Clinical Study Finds Improved Outcomes in Heart Transplant Patients Utilizing Paragonix Advanced Organ Preservation

Paragonix Technologies, Inc., a leading organ transplant company, announced today the publication of groundbreaking research from a clinical study on patient outcomes following heart transplant surgery.

September 7, 2023

·

4 min read

Drug Development

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT217 for Small Cell Lung Cancer and Other Neuroendocrine Cancers Expressing DLL3

Phanes Therapeutics, Inc. announced that the first patient has been dosed in the Phase 1 clinical study of PT217, a first-in-class native IgG-like bispecific antibody targeting DLL3 and CD47 for the treatment of small cell lung cancer and other neuroendocrine tumors.

September 7, 2023

·

2 min read

Gradient Denervation Technologies closes €14m Series A led by Sabadell Asabys

Gradient Denervation Technologies announces the successful closing of a €14m Series A financing that will support ongoing clinical development and evaluation of the ultrasound-based catheter device.

September 7, 2023

·

5 min read

Pharm Country

Quest Diagnostics Releases 2022 Corporate Responsibility Report

Quest Diagnostics, the leader in diagnostic information services, released its 2022 Corporate Responsibility Report.

September 7, 2023

·

3 min read

Lone Star Bio

Natera Announces Pricing of $250 Million Follow-On Offering

Natera, Inc., a global leader in cell-free DNA testing, announced the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share.

September 7, 2023

·

3 min read

Drug Development

Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Valneva SE and Pfizer Inc. announced positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, when given as a booster.

September 7, 2023

·

14 min read

Policy

MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation aiming to improve overall survival in patients undergoing Hematopoietic Stem Cell transplantation

MaaT Pharma announced that the European Medicines Agency has granted MaaT033 orphan drug designation aiming to improve overall survival in patients undergoing HSCT and has recognized the significant benefit that MaaT033 could therefore bring to this patient’s population.

September 7, 2023

·

4 min read

Business

Angle PLC Announces Interim Results for the Period Ended 30 June 2023

ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumor cell diagnostic solutions for the research and diagnostic oncology market, announces its unaudited interim financial results for the six months ended 30 June 2023.

September 7, 2023

·

6 min read